L20 at #ACR23 Phase 3 RCT of #Telitacicept vs. placebo in #RA ☝🏻B-cell neutralization by targeting BlyS and APRIL
Tweet Content
L20 at #ACR23
Phase 3 RCT of #Telitacicept vs. placebo in #RA
☝🏻B-cell neutralization by targeting BlyS and APRIL
✅ better ACR20 and 50 response at W24
✅ favorable structural response
✅ good safety profile
❓ few seronegative patients
A new small molecule to treat #RA?
PAJ https://t.co/fyrqAya41e
Show on Archive Page
On
Display in Search Results
On
PDQ
Off